Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

@article{Norman2012SelectiveJI,
  title={Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.},
  author={Peter Norman},
  journal={Expert opinion on therapeutic patents},
  year={2012},
  volume={22 10},
  pages={1233-49}
}
  • Peter Norman
  • Published 2012 in Expert opinion on therapeutic patents
INTRODUCTION The JAK family comprises of the four non-receptor tyrosine kinases JAK1, JAK2, JAK3 and Tyk2, which play key, but differing, roles in cytokine receptor signal transduction. A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis. Selective inhibition of JAK3, JAK1 or Tyk2 provides the opportunity to achieve clinical efficacy in the treatment of inflammatory diseases while… CONTINUE READING